pubmed-article:9755877 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:9755877 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
pubmed-article:9755877 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
pubmed-article:9755877 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:9755877 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
pubmed-article:9755877 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
pubmed-article:9755877 | lifeskim:mentions | umls-concept:C0332152 | lld:lifeskim |
pubmed-article:9755877 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:9755877 | pubmed:dateCreated | 1998-10-16 | lld:pubmed |
pubmed-article:9755877 | pubmed:abstractText | mAb hCTM01 binds a carcinoma-associated antigen, the MUC1 gene product. The antigen is also present in the circulation, and administration of 111In-labelled hCTM01 results in the formation of immune complexes with enhanced accumulation in the liver. To avoid the unwanted effect of circulating radioactive immune complexes, a strategy to remove the circulating antigen was investigated using a split-dosage schedule. Eleven patients suspected of having ovarian carcinoma were injected with 1 mg/kg unlabelled hCTM01, 1 h before receiving 0.1 mg/kg 111In-labelled hCTM01 (100 M Bq). The amount of radioactivity was determined in resected tumour tissue, various normal tissues and blood samples obtained at laparotomy 6 days postinjection (p.i.). In all patients, the circulating antigen decreased to its nadir after the unlabelled antibody infusion and immune complex formation was demonstrated. Uptake in tumour deposits 6 days p.i. was 11.1 times higher than in normal tissues (P < 0.0001) and 5.9 times higher than in blood (P < 0.0001). 111In activity in liver tissue was comparable to 111In uptake in tumour tissue, and considerably lower than previously reported in patients not pretreated with unlabelled antibody. The split-dosing strategy would appear to be advantageous for use of hCTM01 as a specific carrier for the delivery of cytotoxic agents to patients with ovarian cancer. | lld:pubmed |
pubmed-article:9755877 | pubmed:language | eng | lld:pubmed |
pubmed-article:9755877 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9755877 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:9755877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9755877 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9755877 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:9755877 | pubmed:month | Sep | lld:pubmed |
pubmed-article:9755877 | pubmed:issn | 0340-7004 | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:SymondsE MEM | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:FrierMM | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:BakerT STS | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:RoosJ CJC | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:den... | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:KenemansPP | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:PerkinsA CAC | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:van HofA CAC | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:VerheijenR... | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:MolthoffC FCF | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:SopwithMM | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:WilhelmA JAJ | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:PrinssenH MHM | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:DaviesQQ | lld:pubmed |
pubmed-article:9755877 | pubmed:author | pubmed-author:BroadheadT... | lld:pubmed |
pubmed-article:9755877 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:9755877 | pubmed:volume | 47 | lld:pubmed |
pubmed-article:9755877 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:9755877 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:9755877 | pubmed:pagination | 39-46 | lld:pubmed |
pubmed-article:9755877 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:meshHeading | pubmed-meshheading:9755877-... | lld:pubmed |
pubmed-article:9755877 | pubmed:year | 1998 | lld:pubmed |
pubmed-article:9755877 | pubmed:articleTitle | Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. | lld:pubmed |
pubmed-article:9755877 | pubmed:affiliation | Department of Obstetrics and Gynaecology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands. | lld:pubmed |
pubmed-article:9755877 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9755877 | lld:pubmed |